Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li><keyword id="9735041" type="UNKNOWN" weightage="60" keywordseo="seres-therapeutics">Seres Therapeutics</keyword> soared as much as 608% on Monday after the company announced positive phase 3 trial data for its drug SER-109.</li><li>SER-109 was developed for the potential treatment of C. difficile, which is a bacterial infection of the colon that leads to inflammation and can be deadly.</li><li>Seres said that SER-109 was well tolerated by its trial participants and that it led to a 30.2% decline in the rate of C. difficile recurrence relative to the placebo.</li><li>Seres' market valuation soared from $354 million on Friday to more than $1.5 billion as of Monday afternoon, according to data from YCharts.com</li><li><a href="https://www.businessinsider.com/?hprecirc-bullet?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestedium=ingest" target="_blank" rel="noopener">Visit Business Insider's homepage for more stories</a>.</li></ul>A tiny <keyword id="45082" type="PERSON" weightage="60" keywordseo="biotech">biotech</keyword> stock rewarded investors on Monday after it announced positive phase 3 trial data.The company, <a href="https://markets.businessinsider.com/stocks/mcrb-stock">Seres Therapeutics,</a> <a href="https://www.businesswire.com/news/home/20200810005194/en/Seres-Therapeutics-Announces-Positive-Topline-Results-SER-109">released positive phase 3 trial data</a> for its SER-109 drug, which was being tested for potential treatment of C. difficile.C. difficile is a bacterial infection of the colon that leads to inflammation and can be deadly.Shares of Seres rocketed as much as 608% to $33 on Monday. Investors seem to be impressed by the results. According to Seres, SER-109 was well tolerated by its trial participants and the drug led to a 30% decline in the recurrence of C. difficile relative to the placebo.The biotech's market valuation soared from $354 million as of Friday's close to more than $1.5 billion as of Monday afternoon, according to data from YCharts.com.Read more: <a href="https://www.businessinsider.com/stock-picks-to-buy-cheap-small-mid-cap-companies-jpmorgan-2020-8?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">JPMorgan says buy these 19 'diamond in the rough' stocks that have plunged from yearly highs, but are spring-loaded for huge gains ahead</a>Meanwhile, some investors were betting on the opposite outcome for Seres' clinical trial data. According to ShortSqueeze.com, as of Monday the percentage of shares sold short stood at 17.7%, or 7.4 million shares. The shares sold short that represented a market value of $43.7 million on Friday represented a market value of as much as $245.5 million at Monday's high. That indicates a loss of as much as $201.8 million, assuming no shares sold short were bought back to cover.Short investors may have piled into the stock due to Seres' clinical failure <a href="https://xconomy.com/boston/2017/01/31/seres-dissects-failed-microbiome-drug-trial-suggests-changes-to-fda/#:~:text=Seres%20shares%20plummeted%20more%20than,performed%20when%20ingested%20by%20patients.">four years earlier for the same drug</a> in a phase 2 trial, which led to shares plummeting more than 70%. Seres said it will meet with the FDA to talk about filing for product approval "as soon as possible," according to the news release.<div type="image" title="seres thera.JPG" height="781" width="1154" msid="77472983" hostid="261"></div>

A biotech stock just rocketed 608% after announcing positive phase 3 trial data

<div class="KonaFilter image-container display-table"><div><div class="image on-image"><a href="https://www.flickr.com/photos/niaid/16578744517/">Flickr/NIAID</a></div></div></div><ul><li>The microbiome, or the assortment of all the bugs that live in and on you, have a lot of influence on your overall health.</li><li>It's something researchers are trying to go after to see if targeting the microbiome could in some way treat diseases, or amplify the response people have to other treatments. </li><li>One biotech veteran, who now runs a company focused on the microbiome, sees this as "the next paradigm shift in <keyword id="41551" type="ENTERTAINMENT" weightage="100" keywordseo="science">science</keyword> and medicine."</li></ul> The bugs that live in our gut might one day soon be used to guide the way we treat everything from infections to cancer. Scientists have been working on ways to use the microbiome, or the assortment of microorganisms that live in and on us, to unlock new treatments for difficult diseases. It's led to new companies - both on the medical side and in <a href="http://www.businessinsider.com/healthcare-and-biotech-unicorns-to-watch-2018-1/#11-indigo-agriculture-14-billion-5">agriculture</a> - that are taking a range of approaches to looking at the microbiome. "We look at the microbiome as an organ that they forgot to teach about at medical school," Dr. Roger Pomerantz, CEO of Seres Therapeutics told Business Insider. And it's an incredibly important organ. Say you tried to wipe out all of the bugs that live in and on you - the good and the bad. "You don't end up sick, you end up dead without a microbiome," Pomerantz said. "If that's not an organ, I don't know what is."As humans have changed, so have the microbes that live with us, adapting to <a href="http://www.businessinsider.com/what-affects-your-microbiome-2015-11/">diet, environments,</a> and even our <a href="http://www.businessinsider.com/what-affects-your-microbiome-2015-11/#your-pets-8">furry companions</a>. "We have co-evolved with these organisms for tens of millions of years. They can't live without us, we can't live without them," Pomerantz said. "They're not bad or neutral, they're good and essential."These essential organisms could unlock the next wave of medicine. "I think this is the next paradigm shift in science and medicine," Glenn Nedwin, the CEO of Second Genome, one of the companies focusing on microbiome-based therapies. Nedwin said the potential impact the microbiome might have on medicine could be even bigger than recombinant DNA - technology that enabled scientists to make medications like insulin <a href="http://www.businessinsider.com/insulin-prices-increase-2016-9">so it wouldn't have to come from animals.</a>"Understanding how microbes keep us alive? That has to be much more powerful and have much more of an impact," Nedwin said. <h2>How to use the bugs to make drugs</h2>There are two main ways researchers are looking to use the microbiome to develop therapeutics: the first is using the microorganisms themselves and adding them to a particular ecosystem with the hope that the new bugs will help treat the condition. It's the approach Seres is taking, although it has had its setbacks. In 2016, the company reported that its phase 2 trial that delivered bacterial spores (dormant bacteria) to patients with C. difficile had failed at reducing the relative risk of recurrence.C. difficile infections can occur after a patient's used antibiotics to fight off another infection. The antibiotic wipes or suppresses the good bacteria in your gut, allowing the C. difficile to overpopulate, which can be deadly. Right now, the microbiome is harnessed by using <a href="https://www.hopkinsmedicine.org/gastroenterology_hepatology/clinical_services/advanced_endoscopy/fecal_transplantation.html">fecal matter transplants,</a> in which a healthy donor's stool containing all of his or her microbes is transferred into the sick patient with the hope of restoring a more normal balance to the microbiome.Even so, Seres is pushing forward with a <a href="http://ir.serestherapeutics.com/phoenix.zhtml?c=254006&amp;p=irol-newsArticle&amp;ID=2280220">phase 3 trial</a> that they'll use to approach the FDA for a potential approval. The other is by finding a way to mimic the proteins a particular microbe gives off that seems to be key in a disease, the approach Second Genome is taking. That way, instead of dealing with a living thing, the treatment would just be the protein that's been missing in the body of the sick patient. Second Genome's farthest along treatment is being studied to <a href="http://www.businessinsider.com/what-is-nash-the-silent-liver-disease-that-went-undetected-2017-7">treat NASH</a>, a type of liver disease in which liver fat builds up in people, and in inflammatory bowel disease. <h2>The potential for microbiome-based medicine</h2>The hope is that these approaches lead to new treatments for difficult diseases, or amplify the responses people have to certain treatments. But that'll need a much better understanding of all the microbe strains that are out there, work that's still underway. Once that happens, we may be in a place where we can pinpoint what changes need to take place in a particular person's microbiome that will affect their condition. "You will rationally design the drug that will change your microbiome into a microbiome that affects different diseases," Pomerantz said. When it comes to microbiome-based drugs, there's a lot of potential to use them in conditions that affect the gut, like irritable bowel disorder or C. difficile. But there are a lot of other condition you might not necessarily associate with the gut. Second Genome, for example, is looking at the relationship between <a href="http://www.businessinsider.com/biotech-executives-on-why-2018-is-a-good-year-to-invest-in-the-brain-2018-1">gut microbes and autism</a>. There's a lot of excitement, too, about the potential for the microbiome to better inform why some people respond to <a href="http://www.businessinsider.com/link-between-microbiome-cancer-immunotherapy-skin-cancer-2017-2">a particular cancer treatment</a> that harnesses the body's immune system and others don't. Should researchers find a way to crack this and then create a treatment that could help people respond, it could amplify the effect the drug has on cancer patients. The combination of a microbiome-based drug with the immunotherapy would be a big deal, Pomerantz said. "That is what changes the world," he said. <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/fixed-snoring-and-saved-my-relationship-sleep-apnea-2018-1">Snoring was ruining my relationship - here's how a sleep doctor fixed my sleep apnea</a></h3> <div> </div> </div>

The microbiome has been called the forgotten organ - and it could hold the 'next paradigm shift in science and medicine'

<div class="KonaFilter image-container display-table float_right"><div><div class="image on-image">REUTERS/Stefan WermuthTwo women stop at a mural of David Bowie in Brixton, south London, January 11, 2016.</div></div></div>Good morning! Here's what you need to know.Oil crashed again overnight. US stocks finished higher while West Texas Intermediate crude oil, the US benchmark, fell over 6% and cracked $31 a barrel <a href="http://www.businessinsider.com/closing-bell-january-11-2016-1">at one point for the first time since December 2003. </a>Nestle is targeting products for a healthy gut. The Swss food company is investing in US-based Seres Therapeutics for a third time in a year, this time injecting $120 million to develop and commercialize medicines aimed at restoring a<a href="http://www.businessinsider.com/r-nestle-signs-120-million-deal-with-seres-for-healthy-gut-drugs-2016-1"> healthy bacteriological balance in the human digestive system.</a>Egypt is backing away from its petrol subsidy. Egypt's petroleum minister said the country is "suffering" due to fuel subsidies, saying these funds are better diverted to <a href="http://www.businessinsider.com/ap-oil-minister-says-egypt-suffering-from-fuel-subsidies-2016-1">other areas such as health care and education.</a>Russia is preparing to arm Serbia. Russia is ready to arm its Balkan ally Serbia with sophisticated weapons, the Russian deputy prime minister said, which could be at odds with Belgrade's desire <a href="http://www.businessinsider.com/ap-russia-ready-to-arm-balkan-ally-serbia-2016-1">to join the European Union.</a>Belgium's tax regime is under fire. The EU said tax breaks offered major multinationals in Belgium, including beer giant AB InBev and British American Tobacco, were illegal and ordered the companies <a href="http://www.businessinsider.com/afp-eu-says-belgiums-tax-breaks-for-multinationals-illegal-2016-1">to return €700 million ($762 million) in unpaid taxes.</a>Hong Kong residents are learning about democracy in Taiwan. Hundreds of residents of Hong Kong, the Chinese-ruled territory rocked by street protests demanding free elections in 2014, <a href="http://www.businessinsider.com/r-hong-kong-umbrella-soldiers-visit-boisterous-taiwan-to-see-democracy-at-work-2016-1">have flown to Taiwan for Saturday's elections to see free-wheeling democracy in action.</a>Hillary Clinton is targeting a tax on the rich. The US Democratic presidential candidate is calling for a 4% "surcharge" income tax on people earning more than $5 million annually, <a href="http://www.businessinsider.com/r-clinton-to-propose-four-percent-surcharge-tax-on-high-income-americans-aide-2016-1">a plan expected to raise $150 billion over a decade, a Clinton aide said.</a>Russia has already attacked more than 1,000 targets in Syria in 2016. Russian air force jets have since the start of this year flown 311 combat sorties in Syria and attacked 1,097 terrorist targets there, <a href="http://www.businessinsider.com/r-russia-says-attacked-1097-targets-in-syria-since-new-year-2016-1">Russian news agencies quoted the Russian defense ministry as saying on Monday.</a>France is housing migrants in shipping containers. France opened a migrants' shelter made of converted shipping containers in Calais on its northern Channel coast to try to bring some order to the so-called "jungle" camp in sand dunes near the port. <a href="http://www.businessinsider.com/r-migrant-shelter-made-of-shipping-containers-opens-in-frances-calais-2016-1">The shelter is designed to accommodate up to 1,500 people in 125 white-painted shipping containers.</a>Volkswagen may have to buy its cars back from the US. "In some cases it's very easy to repair the cars, in other cases it's very expensive and in that case we have to negotiate whether it would be better to bring back some of the cars to Volkswagen," <a href="http://www.businessinsider.com/r-vw-may-buy-back-some-cars-in-emissions-scandal-ceo-on-cnbc-2016-1">Matthias Mueller told CNBC at the Detroit auto show.</a> <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/luxury-apartment-prices-manhattan-new-york-city-high-end-record-2016-1">The median sale price of a Manhattan apartment is now $1.15 million</a></h3> <div> <div> <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="V2bGkwMDE6I3Cr3ePvXrpOUg7Rj24Nsc" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div> </div> </div> </div>

You Searched For "seres therapeutics" and got 3 results

A biotech stock just rocketed 608% after announcing positive phase 3 trial data

Matthew Fox

The microbiome has been called the forgotten organ - and it could hold the 'next paradigm shift in science and medicine'

Lydia Ramsey

10 things you need to know before European markets open

Ben Moshinsky

Popular Keywords

Buying Guides